Cargando…

Activity of osimertinib in a patient with stage IV non-small cell lung cancer harboring HER2 exon 19, p.L755P mutation: case report

BACKGROUND: Recurrent in-frame insertions within exon 20 causing duplication of amino acids Tyrosine-Valine-Methionine-Alanine (YVMA) represent 80% of all HER2 alterations in non-small cell lung cancer (NSCLC). HER2 tyrosine kinase inhibitors (TKI), anti-HER2 monoclonal antibodies and HER2 directed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jonsdottir, Gudbjorg, Smith, Mark, Wood, Samuel, Hejleh, Taher Abu, Furqan, Muhammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183391/ https://www.ncbi.nlm.nih.gov/pubmed/37197637 http://dx.doi.org/10.21037/tlcr-22-596

Ejemplares similares

Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer
por: Aung, Kyaw L., et al.
Publicado: (2016)

Distal‐type bronchiolar adenoma of the lung harboring an EGFR exon 21 p.L858R mutation: A case report
por: Yang, Chenglin, et al.
Publicado: (2020)

EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review
por: Pisapia, Pasquale, et al.
Publicado: (2019)

A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib
por: Malapelle, Umberto, et al.
Publicado: (2022)

Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer
por: Field, Matthew G., et al.
Publicado: (2022)

Narrative review: mesenchymal-epithelial transition inhibitors—meeting their target
por: Safi, Danish, et al.
Publicado: (2021)

Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation
por: An, Josiah, et al.
Publicado: (2021)

K+P elastic scattering from 130 to 755 MeV/c
por: Cameron, W, et al.
Publicado: (1974)

P755: STUDIES OF THE SPECIFIC TCIRG1 MUTATIONS CAUSING CONGENITAL NEUTROPENIA
por: Makaryan, Vahagn, et al.
Publicado: (2023)

The Predictive Value of Peripheral Immune Cell Counts for the Presence of Brain Metastases in Stage IV Non-Small-Cell Lung Cancer (NSCLC)
por: Abuelbeh, I, et al.
Publicado: (2022)

P.L. Nervi. Nuevas estructuras.
por: Nervi, Pier Luigi
Publicado: (1963)

Medullary Thyroid Carcinoma With Exon 2 p.L56M RET Variant: Clinical Particular Features in Two Patients
por: Paragliola, Rosa M., et al.
Publicado: (2018)

Novel c.2216T > C (p.I739T) Mutation in Exon 13 and c.1481T > A (p.L494X) Mutation in Exon 8 of MUT Gene in a Female with Methylmalonic Acidemia
por: Imataka, George, et al.
Publicado: (2013)

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
por: Takeda, Masayuki, et al.
Publicado: (2018)

Academician P.L. Kapitza visits CERN
por: CERN PhotoLab
Publicado: (1975)

Report to the LHCC on the staging of L3PL3P-Note-93-13
por: CERN. Geneva. The LHC experiments Committee
Publicado: (1993)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
por: Yang, Chih-Jen, et al.
Publicado: (2017)

755 3D Printed Mouth Stretcher
por: Almendinger, Jana, et al.
Publicado: (2023)

Natural Disease Course in Usher Syndrome Patients Harboring USH2A Variant p.Cys870* in Exon 13, Amenable to Exon Skipping Therapy
por: Čadonič, Katja, et al.
Publicado: (2023)

The complete genome sequence of Clostridium indolis DSM 755(T)
por: Biddle, Amy S., et al.
Publicado: (2014)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Zhang, Xiaoying
Publicado: (2021)

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
por: Joshi, Asim, et al.
Publicado: (2022)

Efficacy of osimertinib in a patient with non-small cell lung cancer harboring epithelial growth factor receptor exon 19 deletion/T790M mutation, with poor performance status
por: Nishii, Yoichi, et al.
Publicado: (2018)

Effective clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in cis-C797S osimertinib to osimertinib and gefitinib combination therapy
por: Wang, Yanyan, et al.
Publicado: (2023)

Bullying and Harassment in Downsized Workplaces: What Can We Learn from the 2008 Icelandic Economic Collapse?
por: Sigursteinsdottir, Hjordis, et al.
Publicado: (2020)

The effects of 755 nm alexandrite laser on skin dryness and pruritus
por: Pancar, Gunseli Sefika, et al.
Publicado: (2020)

755. Clostridioides difficile Testing and the Use of Laxatives in Immunocompromised Adults
por: Al-Bahou, Amanda, et al.
Publicado: (2021)

755. Infectious Diseases Journal Watch: a Pilot Study
por: Chen, Benjamin, et al.
Publicado: (2023)

Pulmonary Pleomorphic Carcinoma Harboring EGFR Mutation Successfully Treated with Osimertinib: A Case Report
por: Kano, Yukari, et al.
Publicado: (2022)

Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015)

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2019)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
por: Cekay, Michael, et al.
Publicado: (2023)

Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report
por: Shan, Jianzhen, et al.
Publicado: (2020)

Impact of Radiotherapy Pattern on the Prognosis of Stage IV Lung Adenocarcinomas Harboring EGFR Mutations
por: Zhang, Yingyun, et al.
Publicado: (2021)

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
por: Makimoto, Go, et al.
Publicado: (2019)

A pulmonary enteric adenocarcinoma patient harboring a rare EGFR exon 19 P753S mutation: Case report and review
por: Xu, Xiaohu, et al.
Publicado: (2022)

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
por: Chen, Yi-Chieh, et al.
Publicado: (2021)

Coronavirus Disease-19: The First 7,755 Cases in the Republic of Korea
Publicado: (2020)

Early embryonic lethality in complex I associated p.L104P Nubpl mutant mice
por: Cheng, Cheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_obflcvl95r5blpsfttrv79a79g